Molecular Partners AG to Present Preclinical Data on DLL3-Targeting Radio-DARPin MP0712 at Upcoming Conferences

Molecular Partners AG will present findings on its DLL3-targeting Radio-DARPin candidate, MP0712, at several upcoming scientific conferences. These presentations will cover various aspects of MP0712, including its preclinical development, mechanism of action, and potential clinical applications.

The presentations will feature data from preclinical studies that evaluate the efficacy and safety of MP0712. Researchers will present details on how MP0712 selectively targets DLL3, a protein overexpressed in certain tumors, and delivers a radioactive payload to cancer cells. The company believes these findings will highlight the potential of MP0712 as a novel therapeutic approach for patients with DLL3-expressing cancers.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 4, 2026

Author

GOAI